Dentsply Sirona Wins Second Covenant Reset in Nine Months
Company Background
Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with approximately $3.7 billion in annual revenue across four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Charlotte, North Carolina company has been executing a self-described "Return-to-Growth Action Plan" since late 2025, following years of operational deterioration, serial goodwill and intangible impairments totaling more than $1.6 billion over 2024 and 2025, and a CFO departure in November 2025.
The financial trajectory has been challenging. Full-year 2025 net sales fell 3.0% to $3.68 billion, with a GAAP net loss of $598 million. The company eliminated its quarterly dividend in early 2026 to redirect capital toward debt reduction and share repurchases. As of June 30, 2026, Dentsply carried approximately $2.22 billion in total debt against $239 million in cash. First-half 2026 adjusted EBITDA totaled $319 million — $129 million in Q1 (down 22.8% year-over-year) and $190 million in Q2 — with the company maintaining its full-year adjusted EPS guidance of $1.40 to $1.50 and net sales guidance of $3.5 billion to $3.6 billion as of August 6–7, 2026.
What Was Disclosed
Dentsply Sirona obtained lender consent for its Third Amendment to the Credit Agreement and the fifth amendments to each of its three note purchase agreements, all dated as of September 30, 2026, with formal consent documented on October 8, 2026. The core mechanics of the amendments are fourfold. First, the maximum permitted Total Leverage Ratio and Senior Leverage Ratio are increased for the fiscal quarters ending September 30, 2026 and December 31, 2026. Second, a new EBITDA addback is permitted for certain cash charges or expenses incurred in those same two quarters — an addback provision that was absent from the prior December 2025 amendments. Third, until delivery of a compliance certificate covering fiscal year 2026, new liens and new subsidiary debt are generally prohibited (with carveouts for items existing before September 30, 2026), and restricted payments — which include dividends and share repurchases — are further limited. Fourth, lenders gain new quarterly reporting rights covering certain initiatives and their associated costs and savings.